1-18 of 18
Elisabeth I. Heath
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes

Justin Hwang, Pornlada Likasitwatanakul, Sachin Kumar Deshmukh, Sharon Wu, Jason J. Kwon, Eamon Toye, David Moline, Mark G. Evans, Andrew Elliott, Rachel Passow, Christine Luo, Emily John, Nishant Gandhi, Rana R. McKay, Elisabeth I. Heath, Chadi Nabhan, Natalie Reizine, Jacob J. Orme, Josep M. Domingo Domenech, Oliver Sartor, Sylvan C. Baca, Scott M. Dehm, Emmanuel S. Antonarakis
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (5): 936–948.
https://doi.org/10.1158/1078-0432.CCR-24-3471
Published: 03 March 2025
View articletitled, Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Open the PDF for Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes in another window
Includes: Supplementary data
Journal Articles

Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial

Charles B. Nguyen, Melissa A. Reimers, Chamila Perera, Wassim Abida, Jonathan Chou, Felix Y. Feng, Emmanuel S. Antonarakis, Rana R. McKay, Russell K. Pachynski, Jingsong Zhang, Zachery R. Reichert, Phillip L. Palmbos, Megan E.V. Caram, Ulka N. Vaishampayan, Elisabeth I. Heath, Alexander C. Hopkins, Marcin P. Cieslik, Yi-Mi Wu, Dan R. Robinson, Veerabhadran Baladandayuthapani, Arul M. Chinnaiyan, Ajjai S. Alva
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (15): 3200–3210.
https://doi.org/10.1158/1078-0432.CCR-24-0400
Published: 01 August 2024
View articletitled, Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Open the PDF for Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial in another window
Includes: Supplementary data
Journal Articles

Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma

Daniel P. Petrylak, Bernhard J. Eigl, Saby George, Elisabeth I. Heath, Sebastien J. Hotte, David D. Chism, Lisle M. Nabell, Joel Picus, Susanna Y. Cheng, Leonard J. Appleman, Guru P. Sonpavde, Alicia K. Morgans, Pourya Pourhosseini, Ruishan Wu, Laura Standley, Ruslan Croitoru, Evan Y. Yu
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (1): 63–73.
https://doi.org/10.1158/1078-0432.CCR-22-3627
Published: 05 January 2024
View articletitled, Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Open the PDF for Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma in another window
Includes: Supplementary data
Journal Articles

Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes

Justin Hwang, Xiaolei Shi, Andrew Elliott, Taylor E. Arnoff, Julie McGrath, Joanne Xiu, Phillip Walker, Hannah E. Bergom, Abderrahman Day, Shihab Ahmed, Sydney Tape, Allison Makovec, Atef Ali, Rami M. Shaker, Eamon Toye, Rachel Passow, John R. Lozada, Jinhua Wang, Emil Lou, Kent W. Mouw, Benedito A. Carneiro, Elisabeth I. Heath, Rana R. McKay, W. Michael Korn, Chadi Nabhan, Charles J. Ryan, Emmanuel S. Antonarakis
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (14): 2702–2713.
https://doi.org/10.1158/1078-0432.CCR-22-3394
Published: 14 July 2023
View articletitled, Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes
Open the PDF for Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes in another window
Includes: Supplementary data
Journal Articles

Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer

Ulka N. Vaishampayan, Archana Thakur, Wei Chen, Abhinav Deol, Meera Patel, Kimberlee Dobson, Brenda Dickow, Dana Schalk, Amy Schienschang, Sarah Whitaker, Amanda Polend, Joseph A. Fontana, Elisabeth I. Heath, Lawrence G. Lum
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (1): 122–133.
https://doi.org/10.1158/1078-0432.CCR-22-1601
Published: 04 January 2023
View articletitled, Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
Open the PDF for Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors

Atish D. Choudhury, Celestia S. Higano, Johann S. de Bono, Natalie Cook, Dana E. Rathkopf, Kari B. Wisinski, Juan Martin-Liberal, Mark Linch, Elisabeth I. Heath, Richard D. Baird, Javier García-Carbacho, Miguel Quintela-Fandino, Simon T. Barry, Elza C. de Bruin, Steve Colebrook, George Hawkins, Teresa Klinowska, Brijesh Maroj, Ganesh Moorthy, Peter G. Mortimer, Michele Moschetta, Myria Nikolaou, Liz Sainsbury, Geoffrey I. Shapiro, Lillian L. Siu, Aaron R. Hansen
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (11): 2257–2269.
https://doi.org/10.1158/1078-0432.CCR-21-3087
Published: 01 June 2022
View articletitled, A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer

Anthony V. Serritella, Daniel Shevrin, Elisabeth I. Heath, James L. Wade, Elia Martinez, Amanda Anderson, Joseph Schonhoft, Yen-Lin Chu, Theodore Karrison, Walter M. Stadler, Russell Z. Szmulewitz
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1549–1559.
https://doi.org/10.1158/1078-0432.CCR-21-4049
Published: 14 April 2022
View articletitled, Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer
Open the PDF for Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer

Rahul R. Aggarwal, Michael T. Schweizer, David M. Nanus, Allan J. Pantuck, Elisabeth I. Heath, Eric Campeau, Sarah Attwell, Karen Norek, Margo Snyder, Lisa Bauman, Sanjay Lakhotia, Felix Y. Feng, Eric J. Small, Wassim Abida, Joshi J. Alumkal
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (20): 5338–5347.
https://doi.org/10.1158/1078-0432.CCR-20-1707
Published: 15 October 2020
View articletitled, A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer
Open the PDF for A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer

Ulka N. Vaishampayan, Izabela Podgorski, Lance K. Heilbrun, Jawana M. Lawhorn-Crews, Kimberlee C. Dobson, Julie Boerner, Karri Stark, Daryn W. Smith, Elisabeth I. Heath, Joseph A. Fontana, Anthony F. Shields
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (2): 652–662.
https://doi.org/10.1158/1078-0432.CCR-18-1473
Published: 15 January 2019
View articletitled, Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer
Open the PDF for Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas

John A. Thompson, Robert J. Motzer, Ana M. Molina, Toni K. Choueiri, Elisabeth I. Heath, Bruce G. Redman, Randeep S. Sangha, D. Scott Ernst, Roberto Pili, Stella K. Kim, Leonard Reyno, Aya Wiseman, Fabio Trave, Banmeet Anand, Karen Morrison, Fernando Doñate, Christian K. Kollmannsberger
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (18): 4399–4406.
https://doi.org/10.1158/1078-0432.CCR-18-0481
Published: 14 September 2018
View articletitled, Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas
Open the PDF for Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas in another window
Includes: Supplementary data
Journal Articles

Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors

Daniel D. Von Hoff, Drew W. Rasco, Elisabeth I. Heath, Pamela N. Munster, Jan H.M. Schellens, Nicolas Isambert, Christophe Le Tourneau, Bert O'Neil, Ron H.J. Mathijssen, Jose A. Lopez-Martin, W. Jeff Edenfield, Miguel Martin, Patricia M. LoRusso, Gordon L. Bray, Jorge DiMartino, Aaron Nguyen, Kejian Liu, Eric Laille, Johanna C. Bendell
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (17): 4072–4080.
https://doi.org/10.1158/1078-0432.CCR-17-3716
Published: 04 September 2018
View articletitled, Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors
Open the PDF for Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial

Channing J. Paller, Xian C. Zhou, Elisabeth I. Heath, Mary-Ellen Taplin, Tina Mayer, Mark N. Stein, Glenn J. Bubley, Roberto Pili, Tamaro Hudson, Radhika Kakarla, Muneer M. Abbas, Nicole M. Anders, Donna Dowling, Serina King, Ashley B. Bruns, William D. Wagner, Charles G. Drake, Emmanuel S. Antonarakis, Mario A. Eisenberger, Samuel R. Denmeade, Michelle A. Rudek, Gary L. Rosner, Michael A. Carducci
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (2): 306–315.
https://doi.org/10.1158/1078-0432.CCR-17-1100
Published: 15 January 2018
View articletitled, Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial
Open the PDF for Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial in another window
Includes: Supplementary data
Journal Articles

A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies

Dejan Juric, Johann S. de Bono, Patricia M. LoRusso, John Nemunaitis, Elisabeth I. Heath, Eunice L. Kwak, Teresa Macarulla Mercadé, Elena Geuna, Maria Jose de Miguel-Luken, Chirag Patel, Keisuke Kuida, Serap Sankoh, Eric H. Westin, Fabian Zohren, Yaping Shou, Josep Tabernero
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (17): 5015–5023.
https://doi.org/10.1158/1078-0432.CCR-16-2888
Published: 31 August 2017
View articletitled, A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies
Open the PDF for A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies in another window
Includes: Supplementary data
Journal Articles

Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin(NPI-2358) in Patients with Solid Tumors or Lymphomas

Monica M. Mita, Matthew A. Spear, Lorrin K. Yee, Alain C. Mita, Elisabeth I. Heath, Kyriakos P. Papadopoulos, Kristine C. Federico, Steven D. Reich, Ofelia Romero, Lisa Malburg, MaryJo Pilat, G. Kenneth Lloyd, Saskia T.C. Neuteboom, Gillian Cropp, Edward Ashton, Patricia M. LoRusso
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (23): 5892–5899.
https://doi.org/10.1158/1078-0432.CCR-10-1096
Published: 06 December 2010
View articletitled, Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin(NPI-2358) in Patients with Solid Tumors or Lymphomas
Open the PDF for Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin(NPI-2358) in Patients with Solid Tumors or Lymphomas in another window
Journal Articles

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2

Joseph Paul Eder, Geoffrey I. Shapiro, Leonard J. Appleman, Andrew X. Zhu, Dale Miles, Harold Keer, Belinda Cancilla, Felix Chu, Suzanne Hitchcock-Bryan, Laurie Sherman, Stewart McCallum, Elisabeth I. Heath, Scott A. Boerner, Patricia M. LoRusso
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (13): 3507–3516.
https://doi.org/10.1158/1078-0432.CCR-10-0574
Published: 01 July 2010
View articletitled, A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2
Open the PDF for A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2 in another window
Journal Articles

A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer

Elisabeth I. Heath, David W. Hillman, Ulka Vaishampayan, Shijie Sheng, Fazlul Sarkar, Felicity Harper, Melvin Gaskins, Henry C. Pitot, Winston Tan, S. Percy Ivy, Roberto Pili, Michael A. Carducci, Charles Erlichman, Glenn Liu
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (23): 7940–7946.
https://doi.org/10.1158/1078-0432.CCR-08-0221
Published: 01 December 2008
View articletitled, A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer
Open the PDF for A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer in another window
Journal Articles

A Phase I Safety and Pharmacologic Study of a Twice Weekly Dosing Regimen of the Oral Taxane BMS-275183

Linda E. Bröker, Stephan A. Veltkamp, Elisabeth I. Heath, Bart C. Kuenen, Helen Gall, Ludovic Astier, Susan Parker, Louis Kayitalire, Patricia M. Lorusso, Jan H.M. Schellens, Giuseppe Giaccone
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (13): 3906–3912.
https://doi.org/10.1158/1078-0432.CCR-06-2875
Published: 02 July 2007
View articletitled, A Phase I Safety and Pharmacologic Study of a Twice Weekly Dosing Regimen of the Oral Taxane BMS-275183
Open the PDF for A Phase I Safety and Pharmacologic Study of a Twice Weekly Dosing Regimen of the Oral Taxane BMS-275183 in another window
Journal Articles

Frequent Hypermethylation of the 5′ CpG Island of E-Cadherin in Esophageal Adenocarcinoma

Paul G. Corn, Elisabeth I. Heath, Richard Heitmiller, Franz Fogt, Arlene A. Forastiere, James G. Herman, Tsung-Teh Wu
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (9): 2765–2769.
Published: 01 September 2001
View articletitled, Frequent Hypermethylation of the 5′ CpG Island of E-Cadherin in Esophageal Adenocarcinoma
Open the PDF for Frequent Hypermethylation of the 5′ CpG Island of E-Cadherin in Esophageal Adenocarcinoma in another window